Hypoxia-inducible factor 2α inhibition in renal cell carcinoma: From von Hippel-Lindau biology to targeted therapeutics.
文献摘要
Clear cell renal cell carcinoma (ccRCC) is characterized by the dysregulation of cellular oxygen sensing resulting from inactivation of the von Hippel-Lindau (VHL) tumor-suppressor gene. Loss of VHL function leads to constitutive activation of hypoxia-inducible factor (HIF) signaling, with HIF-2α emerging as the dominant oncogenic driver of angiogenesis, metabolic reprogramming, tumor growth, and metastasis. The discovery of a druggable cavity within the HIF-2α PAS-B domain transformed a previously undruggable transcription factor into a therapeutic target and enabled the development of selective HIF-2α inhibitors. Belzutifan, the first approved HIF-2α inhibitor, has demonstrated meaningful clinical activity in VHL disease-associated neoplasms and advanced ccRCC, validating direct inhibition of the VHL-HIF pathway as a therapeutic strategy. More recently, belzutifan in combination with pembrolizumab was approved as adjuvant therapy for patients with resected ccRCC. Separately, the development of next-generation HIF-2α inhibitors, HIF-1β (also known as aryl hydrocarbon receptor nuclear translocator)-targeted degraders, and novel combination strategies, including those incorporating vascular endothelial growth factor-targeted therapies, continues to broaden the therapeutic potential of HIF-directed treatment. In this review, the authors summarize the biologic basis of the VHL-HIF axis, the development of HIF-targeted therapies, key clinical data supporting their use in renal cell carcinoma, and future directions for this rapidly evolving therapeutic class.